Discontinued — last reported Q3 '22
Salesforce Acquisitions increased by 742.1% to $8.24B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 271.5%, from $2.22B to $8.24B. Over 4 years (FY 2022 to FY 2026), Acquisitions shows a downward trend with a -31.6% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $425.00M | $14.36B | $35.00M | $60.00M | $414.00M | $25.00M | $0.00 | $0.00 | $0.00 | $0.00 | $82.00M | $0.00 | $338.00M | $0.00 | $179.00M | $2.22B | $0.00 | $54.00M | $978.00M | $8.24B |
| QoQ Change | — | >999% | -99.8% | +71.4% | +590.0% | -94.0% | -100.0% | — | — | — | — | -100.0% | — | -100.0% | — | >999% | -100.0% | — | >999% | +742.1% |
| YoY Change | — | — | — | — | -2.6% | -99.8% | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | +118.3% | — | -100.0% | — | +446.4% | +271.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.